Zobrazeno 1 - 10
of 38
pro vyhledávání: '"I. L. Andrulis"'
Autor:
J. R. B. Perry, Y.-H. Hsu, D. I. Chasman, A. D. Johnson, C. Elks, E. Albrecht, I. L. Andrulis, J. Beesley, G. S. Berenson, S. Bergmann, S. E. Bojesen, M. K. Bolla, J. Brown, J. E. Buring, H. Campbell, J. Chang-Claude, G. Chenevix-Trench, T. Corre, F. J. Couch, A. Cox, K. Czene, A. P. D'adamo, G. Davies, I. J. Deary, J. Dennis, D. F. Easton, E. G. Engelhardt, J. G. Eriksson, T. Esko, P. A. Fasching
Publikováno v:
Human Molecular Genetics
Autor:
Jeremy L. Freeman, Arnold M. Noyek, C. M. McLachlin, S. E. Noble-Topham, I. L. Andrulis, R. W. J. Hartwick, D. M. Fliss
Publikováno v:
Archives of Otolaryngology - Head and Neck Surgery. 119:1299-1304
Objective: This study examined the prevalence and types of human papillomavirus (HPV) DNA in oral cavity verrucous carcinoma. Design: This was of a retrospective screening study. Formalin-fixed, paraffin-embedded tissue samples were examined by the p
Autor:
M K Sauer, I L Andrulis
Publikováno v:
Journal of medical genetics. 42(8)
Background: BRCA1 associated RING domain protein (BARD1) was originally identified due to its interaction with the RING domain of BRCA1. BARD1 is required for S phase progression, contact inhibition and normal nuclear division, as well as for BRCA1 i
Publikováno v:
Cancer. 92(8)
In some malignancies, p53 mutations are associated with tumor progression. To address the role of p53 mutations in the development and progression of osteosarcoma, the authors analyzed specimens from 247 patients with primary localized osteosarcomas
Publikováno v:
Journal of clinical epidemiology. 54(1)
The Ontario Familial Breast Cancer Registry (OFBCR) is one of six international sites of the Cooperative Familial Registry for Breast Cancer Studies collecting family history, epidemiologic information, and blood samples from families (with various p
Publikováno v:
Cancer journal (Sudbury, Mass.). 6(5)
The investigators undertook a retrospective study to determine (1) whether p53 mutations are predictors of survival in patients with advanced epithelial ovarian cancer, (2) whether p53 status by sequencing is associated with established prognostic in
Autor:
U S, Khoo, H Y, Ngan, A N, Cheung, K Y, Chan, J, Lu, V W, Chan, S, Lau, I L, Andrulis, H, Ozcelik
Publikováno v:
Human mutation. 16(1)
Germline mutations in the BRCA1 and BRCA2 genes predispose women to breast and ovarian cancer. An incidence of 5% and 3.3% respectively has been reported of BRCA1 and BRCA2 mutations in women with ovarian cancer unselected for family history. The con
Autor:
K A, Phillips, E, Warner, W S, Meschino, J, Hunter, M, Abdolell, G, Glendon, I L, Andrulis, P J, Goodwin
Publikováno v:
Clinical genetics. 57(5)
The perceived benefits and risks of genetic testing may vary between groups of individuals with different cultural, demographic, and family history features. This multicentre study examined the factors that influenced the decision to undergo genetic
Publikováno v:
Human mutation. 14(6)
Publikováno v:
Journal of surgical oncology. 69(1)
We have previously shown that insulin-like growth factor (IGF)-responsive murine sarcomas demonstrate inhibition of local and metastatic disease growth when implanted in an IGF-deficient host animal. In this experiment, we tested whether IGF receptor